Equities

Dianthus Therapeutics Inc

Dianthus Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)24.29
  • Today's Change-0.64 / -2.57%
  • Shares traded98.03k
  • 1 Year change+113.52%
  • Beta1.8582
Data delayed at least 15 minutes, as of May 10 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to advancing antibody complement therapeutics to treat severe autoimmune diseases. The Company is dedicated to designing and delivering monoclonal antibodies with improved selectivity and potency. The Company has initiated a Phase 2 trial of DNTH103, a potential active C1s inhibitor, in generalized Myasthenia Gravis and plans to initiate additional Phase 2 trials in other neuromuscular indications, including Multifocal Motor Neuropathy and Chronic Inflammatory Demyelinating Polyneuropathy. Its product candidate, DNTH103, is a clinical-stage, highly potent, highly selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of the C1s complement protein. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile.

  • Revenue in USD (TTM)3.22m
  • Net income in USD-50.21m
  • Incorporated2015
  • Employees53.00
  • Location
    Dianthus Therapeutics Inc300 Technology Square, 8Th FloorCAMBRIDGE 02139United StatesUSA
  • Phone+1 (857) 201-2700
  • Fax+1 (302) 655-5049
  • Websitehttps://dianthustx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Castle Biosciences Inc250.73m-30.80m669.20m610.00--1.66--2.67-1.15-1.159.2814.590.56648.017.12411,024.60-6.96-9.43-7.48-10.1780.5880.58-12.28-28.469.02--0.0243--60.3857.3514.41--117.94--
Mineralys Therapeutics Inc0.00-90.80m671.01m28.00--2.05-----2.18-2.180.006.610.00----0.00-27.78---29.11--------------0.00-------141.28------
Prime Medicine Inc0.00-198.13m673.36m234.00--4.11-----2.17-2.170.001.370.00----0.00-71.51---84.13-------------85.970.00-------39.52------
Wave Life Sciences Ltd112.91m-61.67m687.43m266.00--27.08--6.09-0.5152-0.51520.99850.27190.4494----424,488.70-24.54-56.98-60.43-102.38-----54.61-353.20--------3,005.1051.0464.46---35.44--
Hillevax Inc0.00-143.51m688.14m90.00--2.88-----2.33-2.330.004.810.00----0.00-46.66---50.34--------------0.0963------22.68------
Phibro Animal Health Corp999.56m13.16m710.84m1.92k54.022.6314.590.71120.32490.324924.686.671.032.426.37520,606.301.355.461.666.8330.3331.411.325.111.672.260.642742.993.783.59-33.69-13.5622.803.71
Dianthus Therapeutics Inc3.22m-50.21m712.88m53.00--1.91--221.12-3.20-3.200.272112.700.0138----60,830.19-21.56-41.40-22.27-44.70-----1,557.51-12,132.27----0.00------43.04---57.21--
SAGE Therapeutics Inc91.06m-503.14m716.17m487.00--1.01--7.86-8.40-8.401.5211.730.0916--6.26186,989.70-50.61-21.88-54.64-23.3096.4999.63-552.52-131.50----0.00--1,024.84-0.8606-1.63---28.01--
Aurinia Pharmaceuticals Inc191.41m-62.56m717.96m300.00--2.01--3.75-0.4363-0.43631.342.500.39530.60087.98638,023.30-12.92-25.97-14.63-28.2488.78---32.69-137.645.05--0.1843--30.95227.9027.88--57.11--
Cogent Biosciences Inc0.00-212.17m722.84m164.00--3.61-----2.47-2.470.004.420.00----0.00-57.40-49.53-62.27-54.94-------1,684.44----0.00-------37.20--38.48--
SS Innovations International Inc5.88m-20.94m725.58m239.00--50.74--123.40-0.1293-0.12930.040.08380.3939--2.5324,601.30-140.31-161.38-253.40-449.7612.13-79.79-356.17-495.771.30-52.510.2963-------846.31--159.31--
Arcturus Therapeutics Holdings Inc124.53m-107.30m734.06m180.00--2.78--5.89-4.02-4.024.669.810.2799--2.08691,811.10-24.12-19.66-31.37-24.90-----86.16-77.55----0.00---19.0360.31-417.95--14.44--
National Research Corporation147.42m30.36m741.45m435.0024.96--20.415.031.241.246.02--1.16--11.56338,896.6023.8026.2535.6736.7762.2963.2020.6023.95--132.000.532555.45-1.974.42-2.580.669521.45-5.29
Disc Medicine Inc0.00-80.60m750.54m74.00--2.22-----3.37-3.370.0013.690.00----0.00-26.96---28.13--------------0.00-------63.22------
CARGO Therapeutics Inc0.00-98.15m751.55m116.00--1.94-----2.37-2.370.009.84------0.00--------------------0.00-------139.67------
Data as of May 10 2024. Currency figures normalised to Dianthus Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

42.64%Per cent of shares held by top holders
HolderShares% Held
Avidity Partners Management LPas of 22 Jan 20242.72m9.26%
Fairmount Funds Management LLCas of 22 Jan 20242.58m8.79%
RA Capital Management LPas of 01 Apr 20242.33m7.95%
Fidelity Management & Research Co. LLCas of 31 Dec 20232.22m7.56%
Octagon Capital Advisors LPas of 31 Dec 2023554.00k1.89%
HSBC Portf�y Y�netim ASas of 29 Mar 2024539.00k1.84%
The Vanguard Group, Inc.as of 31 Mar 2024535.42k1.82%
Tang Capital Management LLCas of 31 Dec 2023504.24k1.72%
Nantahala Capital Management LLCas of 31 Dec 2023328.43k1.12%
Susquehanna Financial Group LLLPas of 31 Mar 2024205.49k0.70%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.